Attachment
Gates Package, p.228 · gates:exh:00121
Page text: p.228 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
- Topics
- Vaccines
G1 - NIAID DIR collaborative agreements active between June 1 2016 and Dec 13 2023
Reference# I Agreement Type
Effective Date Expiration Dz External Parties
*Lead Pl
2019-1323
Research Collaboration Agreement
7/13/2020]
7/14/2023|Adaptive Biotechnologies Corp.
John Kash
2019-1323
Research Collaboration Agreement
7/13/2020]
7/14/2023|Adaptive Biotechnologies Corp.
John Kash
2019-1454
Gift
3/17/2020]
4/30/2024] California Institute of Technology (Caltech)
Malcolm Martin
European Society for Paediatric Infectious Diseases
2019-1456
Gift
3/10/2020}
3/10/2021} (ESPID)
European Society for Paediatric Infectious Diseases
2019-1456
Gift
3/10/2020}
3/10/2021] (ESPID)
2019-1487
Letter of Intent/MOU
3/2/2020]
GlaxoSmithKline (GSK)
Amy Klion
2019-1490
Letter of Intent/MOU
2/28/2020]
8/31/2024|Battelle Memorial Institute - Columbus Operations
|Theodore Pierson
National Institute of Biomedical Research (INRB,
2019-1494
Letter of Intent/MOU
6/28/2019
Institut National de la Recherche Bio) [CD]
Anthony Fauci
National Center for Advancing Translational
Sciences (NCATS/NIH), University of Oxford (incl Isis
2019-1495
Research Collaboration Agreement
3/4/2020}
3/4/2023||nnovation, The Chancellor, Masters and Scholars I Carole Long
2020-0026
Research Collaboration Agreement
6/15/2020)
CureVac AG [DE]
Vincent Munster
National Cancer Institute (NCI/NIH), National
Center for Advancing Translational Sciences
(NCATS/NIH), National Heart, Lung and Blood
Institute (NHLBI/NIH), National Institute of Arthritis
2020-0045
Research Collaboration Agreement
1/31/2020]
_1/31/2024]and Musculoskeletal and Skin Diseases (NIAMS/NIH
|Iain Fraser
2020-0052
Gift
3/5/2020
Creutzfeldt-Jakob Disease (CJD) Foundation, Inc.
Byron Caughey
2020-0053
Gift
1/17/2020)
Arthritis National Research Foundation (ANRF)
Daniella Schwartz
2020-0187
CTA - Clinical Trial Agreement
3/2/2021
Gilead Sciences, Inc
2020-0213
CTA - Clinical Trial Agreement
2/24/2020
Pfizer, Inc.
Raphaela Goldbac
2020-0240
Letter of Intent/MOU
8/17/2020]
8/12/2021|Genentech, Inc.
Amy Klion
2020-0274
CRADA
6/25/2020}
12/25/2023 |PharmAbcine
Kirk Druey
National Cancer Institute (NCI/NIH), NIH Clinical
2020-0277
CRADA
7/13/2020)
11/2/2023|Center (CC/NIH), Nvidia Corporation
Steven Holland